The effect of oral vitamin D and vitamin B on Treatment of vitiligo

To compare the improvement of Non-segmental Vitiligo patients with topical PUVA-therapy alone, topical PUVA-therapy and oral vitamin D, topical PUVA-therapy and oral vitamin D and oral vitamin B.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016100527404N4

Enrollment

Registered

2016-10-21

Start date

2015-01-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo. Vitiligo

Interventions

Intervention 1: In the first group Intervention: Patients were treated for 6 months with an initial dose of 0.12 to 0.25 mJ/cm2 of topical PUVA therapy for 2 times per week. Intervention 2: In the sec

Treatment - Drugs

In the first group Intervention: Patients were treated for 6 months with an initial dose of 0.12 to 0.25 mJ/cm2 of topical PUVA therapy for 2 times per week.

In the second group Intervention: Patients at the initial 2 months of treatment, in addition to receiving topical treatment of PUVA therapy,daily 1 cc oral drops vitamin D3( 1000 IU company BIOVITATIC

In the third group intervention: Patients at the initial 2 months of treatment, in addition to receiving topical treatment of PUVA therapy, daily 1 cc oral drops vitamin D3( 1000 IU company BIOVITATIC

Eligibility

Sex/Gender

All

Age

12 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- patients with stable vitiligo 2- Aged between 12 and 60 years. 3- not pregnant or lactating. 4- not acral vitiligo 5- There is not history of severe nephrolithiasis and hypersensitivity to vitamin D or vitamin B. 6- Involvement less than 20% body surface area. 7- Site of the lesion not on the face. 8- No Prohibition use of methoxsalen. Exclusion criteria: 1-lack of desire to continue cooperation 2-pregnant patients during the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pigmentation. Timepoint: Before and after treatment. Method of measurement: VASI score.;Extent lesion. Timepoint: Before and after treatment. Method of measurement: VASI score.;Peri follicular repigmentation. Timepoint: Before and after treatment. Method of measurement: questionnaire.	—

Secondary

Measure	Time frame
Erythema. Timepoint: In 1,2,3,4,5,6 month treatment. Method of measurement: questionnaire.;Blisters. Timepoint: In 1,2,3,4,5,6 month treatment. Method of measurement: questionnaire.;Itching. Timepoint: In 1,2,3,4,5,6 month treatment. Method of measurement: questionnaire.;The recurrence. Timepoint: In 1,2,3,4,5,6 month treatment. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactdr elahe haftbaradaran

Skin Diseases and Leishmaniasis Research Center

elahe_md2003@yahoo.com+98 31 3339 0100

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026